The report provides a detailed analysis essential for establishing a Crizotinib production plant. It encompasses all critical aspects necessary for Crizotinib production, including the cost of Crizotinib production, Crizotinib plant cost, Crizotinib production costs, and the overall Crizotinib production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Crizotinib production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.
Crizotinib is an anticancer drug used to treat lung cancer. It is intended for people with metastatic non-small cell lung cancer (NSCLC) whose tumors have genetic alterations known as ROS1 or ALK. This implies that before prescribing Crizotinib, physicians use a specific test to look for these alterations. In children one year of age and older, Crizotinib is used to treat systemic anaplastic large cell lymphoma (ALCL), provided that the malignancy is ALK-positive. By preventing signals that aid in the growth of cancer cells, Crizotinib slows or completely stops the spread of the disease.
The procurement of Crizotinib is influenced by its utilization in the pharmaceutical and medical industries as an anticancer medication used to treat lung cancer. The widespread occurrence of lung cancers is significantly increasing the demand for Crizotinib. The application of Crizotinib in other cancers such as anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumors (IMT), amplifies its market presence.
Crizotinib has a high probability of being more cost-effective than traditional chemotherapy and outperforms standard treatments in terms of cost-effectiveness, which accelerates its market demand. Additionally, the ability of the medication to achieve high objective response rates and improved progression-free survival compared to traditional chemotherapy options contributes to its market growth. Overall, industrial Crizotinib procurement is influenced by its utilization in the pharmaceutical and medical industries, rising cases of lung cancers, cost-effectiveness, greater efficacy, higher potency than standard medications, enhanced survival rates, and regulatory approvals.
Raw Material for Crizotinib Production
According to the Crizotinib production plant project report, the key raw material used in the production of Crizotinib includes 2-aminopyridin-3-ol.
Production Process of Crizotinib
The extensive Crizotinib production cost report consists of the following major industrial production process:
- Production from 2-aminopyridin-3-ol: The production process of Crizotinib starts with the reaction of the starting compound with bis(trichloromethyl)carbonate (BTC) to form an oxazole compound. The oxazole compound undergoes bromination with bromine to give a bromide derivative. The bromide is subjected to hydrolysis in NaOH solution to give an intermediate. The amino group of the intermediate is protected by the Boc group to produce another intermediate. The intermediate is coupled with (S)-1-(2,6-dichloro-3- fluorophenyl)ethanol to form the final intermediate. The intermediate undergoes Suzuki coupling with boronate by using Pd(Ph3P)2Cl2 as a catalyst in DMF to form Di-Boc protected compound. Finally, the Boc groups of the compound are removed with HCl in ethanol to give Crizotinib.
Crizotinib, commercially known as Xalkori, is a white to pale yellow powder having the molecular formula C21H22Cl2FN5O and a molecular weight of 450.3 g/mol. It has a log P value of 1.83. The value of its dissociation constant, pKa, is in the range of 5.6-9.4. It is almost insoluble in water, with an estimated water solubility of around 0.00611 mg/mL. It dissolves in DMSO and ethanol. It is an inhibitor of the tyrosine kinase receptor, used to treat lung cancer.
